Sarissa Capital Management LP bought a new position in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 182,300 shares of the biopharmaceutical company’s stock, valued at approximately $10,649,000. Intercept Pharmaceuticals makes up approximately 2.7% of Sarissa Capital Management LP’s investment portfolio, making the stock its 7th biggest position. Sarissa Capital Management LP owned about 0.73% of Intercept Pharmaceuticals as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Senvest Management LLC lifted its stake in Intercept Pharmaceuticals by 66.3% in the 4th quarter. Senvest Management LLC now owns 970,926 shares of the biopharmaceutical company’s stock worth $56,721,000 after purchasing an additional 387,136 shares in the last quarter. First Trust Advisors LP lifted its stake in Intercept Pharmaceuticals by 101.5% in the 4th quarter. First Trust Advisors LP now owns 605,454 shares of the biopharmaceutical company’s stock worth $35,371,000 after purchasing an additional 304,999 shares in the last quarter. Altrinsic Global Advisors LLC lifted its stake in Intercept Pharmaceuticals by 33.4% in the 4th quarter. Altrinsic Global Advisors LLC now owns 310,300 shares of the biopharmaceutical company’s stock worth $18,128,000 after purchasing an additional 77,756 shares in the last quarter. Pinnacle Associates Ltd. purchased a new position in Intercept Pharmaceuticals in the 4th quarter worth approximately $12,577,000. Finally, Spark Investment Management LLC lifted its stake in Intercept Pharmaceuticals by 43.9% in the 4th quarter. Spark Investment Management LLC now owns 181,110 shares of the biopharmaceutical company’s stock worth $10,580,000 after purchasing an additional 55,210 shares in the last quarter. 74.33% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have weighed in on the stock. Oppenheimer reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Monday, January 29th. Wedbush reaffirmed an “outperform” rating and set a $253.00 price target (down previously from $256.00) on shares of Intercept Pharmaceuticals in a research report on Friday. Citigroup set a $74.00 price target on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, December 21st. ValuEngine downgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $253.00 target price (down previously from $332.00) on shares of Intercept Pharmaceuticals in a report on Thursday, January 25th. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. Intercept Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $128.75.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.04). The business had revenue of $37.69 million during the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. The firm’s revenue for the quarter was up 173.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($4.84) earnings per share. equities analysts anticipate that Intercept Pharmaceuticals Inc will post -12.68 EPS for the current fiscal year.
Intercept Pharmaceuticals Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.